| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ifnar1 |
| Uniprot No | P17181 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-436aa |
| 氨基酸序列 | KNLKSPQKVEVDIIDDNFILRWNRSDESVGNVTFSFDYQKTGMDNWIKLS GCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSFTPFRKAQ IGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVE ERIENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVEN ELPPPENIEVSVQNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKW KQIPDCENVKTTQCVFPQNVFQKGIYLLRVQASDGNNTSFWSEEIKFDTE IQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTPVIQDYPLIYEIIFWENT SNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSVFSDAVCE KTKPGNTSK |
| 预测分子量 | 74 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3条与Ifnar1重组蛋白相关的文献摘要信息：
1. **文献名称**：*Cloning and expression of a recombinant human type-I interferon receptor*
**作者**：Uzé, G., Lutfalla, G., Gresser, I.
**摘要**：该研究首次成功克隆并表达了人源Ifnar1重组蛋白，验证其与干扰素α/β的结合能力，并证实其在细胞信号转导中的关键作用。
2. **文献名称**：*Structural basis of interferon receptor assembly and signaling*
**作者**：Schneider, W.M., Chevillotte, M.D., Rice, C.M.
**摘要**：通过X射线晶体学解析Ifnar1重组蛋白的胞外结构域，揭示其与干扰素及Ifnar2的相互作用机制，阐明受体复合物激活下游信号通路的分子基础。
3. **文献名称**：*Targeting IFNAR1 degradation in autoimmune disease*
**作者**：Li, Z., et al.
**摘要**：利用Ifnar1重组蛋白筛选小分子抑制剂，发现其通过促进受体降解抑制过度干扰素信号，为红斑狼疮等自身免疫疾病提供潜在治疗策略。
(注：以上内容为文献核心信息概括，具体文献需通过学术数据库检索验证。)
**Background of IFNAR1 Recombinant Protein**
Interferon alpha/beta receptor 1 (IFNAR1) is a critical component of the type I interferon (IFN) signaling system, which plays a central role in innate immune responses against viral infections and immune regulation. As a transmembrane protein, IFNAR1 pairs with IFNAR2 to form the functional receptor complex for type I IFNs, including IFN-α and IFN-β. Upon ligand binding, IFNAR1 undergoes conformational changes that activate downstream JAK-STAT signaling pathways, leading to the expression of interferon-stimulated genes (ISGs) with antiviral, antiproliferative, and immunomodulatory activities.
Recombinant IFNAR1 proteins are engineered versions of the extracellular domain of the receptor, often produced in mammalian or insect cell systems to ensure proper post-translational modifications. These proteins retain the ability to bind type I IFNs with high affinity, making them valuable tools for studying IFN-receptor interactions, blocking endogenous IFN signaling in experimental models, or developing therapeutic strategies. For instance, soluble IFNAR1 can act as a decoy receptor to neutralize excessive IFN activity in autoimmune diseases like systemic lupus erythematosus (SLE) or mitigate cytokine storms in severe viral infections.
Research applications of IFNAR1 recombinant proteins include elucidating mechanisms of viral immune evasion, screening for IFN pathway modulators, and optimizing immunotherapies. In drug development, they serve as standards in assays or candidates for biologic therapies targeting dysregulated IFN signaling. Understanding IFNAR1 structure-function relationships through recombinant proteins has also advanced the design of engineered interferons with improved specificity and reduced side effects. Overall, IFNAR1 recombinant proteins are pivotal in bridging basic research and clinical innovation in immunology and virology.
×
